Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023. In the quarter to September 2025, revenue fell 36.4%, EPS grew 78.3% and free cash flow fell 41.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow LIPO
Lipella Pharmaceuticals Inc. (LIPO) EV/Sales
As of 16 October 2026, Lipella Pharmaceuticals Inc. (LIPO) trades at a EV/Sales of −3.3×. Over the past ten years it has ranged from −4.5× (June 2025) to 23.3× (July 2023); the current reading is higher than 6% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 2.4× | (58.58%) |
| FY2023 | 5.9× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | 2.7× | 12.85% |
| Mar 2025 | 2.4× | (2.60%) |
| Dec 2024 | 2.4× | (62.78%) |
| Sep 2024 | 6.6× | 31.32% |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIPO Lipella Pharmaceuticals Inc. | −3.3× |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| IOBTQ IO Biotech, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| UNBX UNITY Biotechnology, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 18.3× |
| ERNA Ernexa Therapeutics Inc. compare | 51.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)